DE3825374A1 - Komplex aus mindestens einer lipophilen saeure und mitoxantron und/oder bisantren - Google Patents

Komplex aus mindestens einer lipophilen saeure und mitoxantron und/oder bisantren

Info

Publication number
DE3825374A1
DE3825374A1 DE3825374A DE3825374A DE3825374A1 DE 3825374 A1 DE3825374 A1 DE 3825374A1 DE 3825374 A DE3825374 A DE 3825374A DE 3825374 A DE3825374 A DE 3825374A DE 3825374 A1 DE3825374 A1 DE 3825374A1
Authority
DE
Germany
Prior art keywords
complex
mitoxantrone
bisantrene
composition
lipophilic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE3825374A
Other languages
German (de)
English (en)
Other versions
DE3825374C2 (https=
Inventor
Reto Schwendener
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SCHWENDENER RETO DIPL APOTHEKE
Original Assignee
SCHWENDENER RETO DIPL APOTHEKE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SCHWENDENER RETO DIPL APOTHEKE filed Critical SCHWENDENER RETO DIPL APOTHEKE
Priority to DE3825374A priority Critical patent/DE3825374A1/de
Publication of DE3825374A1 publication Critical patent/DE3825374A1/de
Application granted granted Critical
Publication of DE3825374C2 publication Critical patent/DE3825374C2/de
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C07F9/106—Adducts, complexes, salts of phosphatides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/24—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings
    • C07C225/26—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings
    • C07C225/32—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings of condensed quinone ring systems formed by at least three rings
    • C07C225/34—Amino anthraquinones
    • C07C225/36—Amino anthraquinones the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/24—Anthracenes; Hydrogenated anthracenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE3825374A 1988-07-26 1988-07-26 Komplex aus mindestens einer lipophilen saeure und mitoxantron und/oder bisantren Granted DE3825374A1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE3825374A DE3825374A1 (de) 1988-07-26 1988-07-26 Komplex aus mindestens einer lipophilen saeure und mitoxantron und/oder bisantren

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3825374A DE3825374A1 (de) 1988-07-26 1988-07-26 Komplex aus mindestens einer lipophilen saeure und mitoxantron und/oder bisantren

Publications (2)

Publication Number Publication Date
DE3825374A1 true DE3825374A1 (de) 1990-02-01
DE3825374C2 DE3825374C2 (https=) 1990-06-28

Family

ID=6359585

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3825374A Granted DE3825374A1 (de) 1988-07-26 1988-07-26 Komplex aus mindestens einer lipophilen saeure und mitoxantron und/oder bisantren

Country Status (1)

Country Link
DE (1) DE3825374A1 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992001441A1 (de) * 1990-07-21 1992-02-06 Knoll Aktiengesellschaft Stabile wirkstoff-formulierung
WO1993018749A1 (de) * 1992-03-17 1993-09-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Liposomen mit negativer überschussladung
EP1159974A1 (en) * 1993-07-19 2001-12-05 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
US6846841B2 (en) 1993-07-19 2005-01-25 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
EP1838286B1 (de) * 2004-12-23 2012-02-15 KTB Tumorforschungsgesellschaft mbH Herstellung von lipidbasierten nanopartikeln unter einsatz einer dualen asymmetrischen zentrifuge
EP3024457A4 (en) * 2013-07-26 2017-06-28 Update Pharma Inc. Compositions to improve the therapeutic benefit of bisantrene
WO2019073296A1 (en) * 2017-10-13 2019-04-18 Race Oncology Ltd. LIPOSOMAL FORMULATIONS OF BISANTRENE OR DERIVATIVES OR THE LIKE THEREOF

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19818802A1 (de) * 1998-04-27 1999-10-28 Dresden Arzneimittel Stabile Mitoxantron-Lösungen

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3343530A1 (de) * 1983-12-01 1985-06-13 Max Planck Gesellschaft Arzneimittel mit verbesserter penetration der gewebsmembran

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3343530A1 (de) * 1983-12-01 1985-06-13 Max Planck Gesellschaft Arzneimittel mit verbesserter penetration der gewebsmembran

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Angew. Chemie 97, 1985, S. 157-159 *
CA 104, 1986, 141 894 x *
LIST, Arzneiformenlehre 1985, 518-520 *
RÖMPP: Chemie-Lexikon, 1983, 2379 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992001441A1 (de) * 1990-07-21 1992-02-06 Knoll Aktiengesellschaft Stabile wirkstoff-formulierung
WO1993018749A1 (de) * 1992-03-17 1993-09-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Liposomen mit negativer überschussladung
AU672600B2 (en) * 1992-03-17 1996-10-10 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Liposomes with excess negative charge
US5626867A (en) * 1992-03-17 1997-05-06 Max-Planck Gesellschaft Zur Forderung Der Wissenschaften E.V. Liposomes with a negative excess charge
EP1159974A1 (en) * 1993-07-19 2001-12-05 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
EP1155691A3 (en) * 1993-07-19 2002-05-29 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
US6544544B2 (en) 1993-07-19 2003-04-08 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
US6846841B2 (en) 1993-07-19 2005-01-25 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
EP1838286B1 (de) * 2004-12-23 2012-02-15 KTB Tumorforschungsgesellschaft mbH Herstellung von lipidbasierten nanopartikeln unter einsatz einer dualen asymmetrischen zentrifuge
US10662060B2 (en) 2004-12-23 2020-05-26 Ulrich Massing Manufacture of lipid-based nanoparticles using a dual asymmetric centrifuge
EP3024457A4 (en) * 2013-07-26 2017-06-28 Update Pharma Inc. Compositions to improve the therapeutic benefit of bisantrene
US10500192B2 (en) 2013-07-26 2019-12-10 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
US10548876B2 (en) 2013-07-26 2020-02-04 Race Oncology Ltd. Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
US11135201B2 (en) 2013-07-26 2021-10-05 Race Oncology Ltd. Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
US11147800B2 (en) 2013-07-26 2021-10-19 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
WO2019073296A1 (en) * 2017-10-13 2019-04-18 Race Oncology Ltd. LIPOSOMAL FORMULATIONS OF BISANTRENE OR DERIVATIVES OR THE LIKE THEREOF

Also Published As

Publication number Publication date
DE3825374C2 (https=) 1990-06-28

Similar Documents

Publication Publication Date Title
DE69431750T2 (de) Multivesikuläre liposomen mit verkapseltem cyclodextrin und pharmakologisch wirksamen verbindungen sowie verfahren zu deren verwendung
DE69837339T2 (de) Veränderung der Wirkstoffladung in multivesikulären Liposomen
DE69725747T2 (de) Liposome enthaltend cisplatin
DE69627690T2 (de) Liposomale formulierungen von mitoxantron
DE3686797T2 (de) Emulsionen zur verabreichung in wasser schwerloeslicher ionisierbarer basischer hydrophober arzneistoffe.
DE60030965T2 (de) Konjugate enthaltend eine spaltbare bindung zur anwendung in einem liposom
DE69907243T2 (de) In liposomen eingeschlossene topoisomerase inhibitoren
DE69426418T2 (de) Feste fettnanoemulsionen als wirkstoffabgabevehikel
DE3786555T2 (de) Vermehrte herstellung von mit liposomen eingekapseltem hämoglobin.
DE69530368T2 (de) Vinca-alkaloid vesikel mit erhöhter wirksamkeit und tumor-zielausrichtung
DE69218241T2 (de) Arzneistofformulierung zur parenteralen anwendung
DE3686221T2 (de) Emulsionen zur parenteralen und/oder oralen verabreichung schwer wasserloeslicher ionisierbarer hydrophober arzneistoffe.
EP0317120B1 (en) Improved amphotericin b liposome preparation
DE60115045T2 (de) Verbesserte liposomale camptothecine und deren verwendungen
DE69713615T2 (de) Ionophorenvermitteltes aufladen von liposomen mit schwach basischen arzneistoffen
DE69624485T2 (de) Verfahren zur herstellung hydro-monobenzoporhyrin -photosensibilisatoren enthaltender liposomen
DE3856550T2 (de) LUV mit gesättigten Phospholipiden und Verfahren zu deren Herstellung
DE69935435T2 (de) Mittels Ammoniumsulfatgradient hergestellte liposomale analgetische Zusammensetzungen
DE69923315T2 (de) Verfahren zur herstellung von liposomen
DE69008729T2 (de) Verfahren zur herstellung einer öl-in-wasser-emulsion eines wirkstoffes.
EP0056781A2 (de) Verfahren zur Herstellung von liposomalen Arzneimitteln
DE69432320T2 (de) Fusogene liposomen und verfahren zu deren herstellung und verwendung
DE69018460T2 (de) Markierung mit liposomen von ischämischen geweben.
DE69924004T2 (de) Verabreichungssystem für wasserunlösliche arzneistoffe
DE60110057T2 (de) Liposomen enthaltend eine eingeschlossene verbindung in übersattigter lösung

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
D2 Grant after examination
8364 No opposition during term of opposition